# Phase I/II Trial of IMA950 Multi-peptide Vaccine Plus Poly-ICLC in Glioblastoma

> **NCT01920191** · PHASE1,PHASE2 · COMPLETED · sponsor: **University Hospital, Geneva** · enrollment: 19 (actual)

## Conditions studied

- CNS Tumor, Adult

## Interventions

- **BIOLOGICAL:** IMA 950
- **BIOLOGICAL:** Poly ICLC
- **OTHER:** Immunomonitoring

## Key facts

- **NCT ID:** NCT01920191
- **Lead sponsor:** University Hospital, Geneva
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-08
- **Primary completion:** 2016-03
- **Final completion:** 2016-03
- **Target enrollment:** 19 (ACTUAL)
- **Last updated:** 2016-04-20

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01920191

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01920191, "Phase I/II Trial of IMA950 Multi-peptide Vaccine Plus Poly-ICLC in Glioblastoma". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01920191. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*